FEEDBACK
PLEASE WAIT ...
CLOSE
CLOSE

Country

Document

No Title 0.56 MB
Registration Date 3 Sep 2022
Revision Date 3 Sep 2022
Share

Zevalin

(0)

Medicine Pharmaceuticals

anticancer drug

Drug Information

Generic
Ibritumomab Tiuxetan
Drug Class
Chemotherapy
Therapeutic Class
Antineoplastic Agent
Dosage form
Solution
Route of Administration
Intravenous Injection
Therapeutic Area
1.Lymphoma

Nanomaterials

Manufacturer Asserted

Protein

Nanoparticle /Nanopowder

Indication

ZEVALIN® (ibritumomab tiuxetan) injection for intravenous use is a prescription medication that has three parts: two infusions of rituximab and one injection of Yttrium-90 (Y-90) ZEVALIN. Rituximab is used to reduce the number of B-cells in your blood and Y-90 ZEVALIN is given to treat your non-Hodgkin’s lymphoma (NHL). The ZEVALIN therapeutic regimen is used to treat adult patients with: Relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL) Previously untreated follicular NHL who achieve a partial or complete response to first-line chemotherapy

Benefit

Zevalin is an immunoconjugate between the monoclonal antibody ibritumomab and the linker-chelator tiuxetan arising from the stable thiourea covalent link. This linker-chelator offers an Indium-111 or Yttrium-90.0 site for high affinity, conformationally limited chelation. Ibritumomab tiuxetan has an average molecular mass of 148 kDa. Ibritumomab, a murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, is the antibody moiety of zevalin. Ibritumomab tiuxetan is a transparent, colorless, sterile, preservative-free, pyrogen-free solution containing fine particles. It is provided in single-use vials containing 3.2 mg of ibritumomab in 2 mL of 0.9% sodium chloride. Zevalin is a protein used in conjunction with other drugs to treat non-Hodgkin lymphoma that attacks white blood cells. Zevalin injection for intravenous use is a prescription medication that has three parts: two infusions of rituximab and one injection of Yttrium-90 Zevalin. Rituximab is used to reduce the number of B-cells in your blood and Y-90 Zevalin is given to treat your non-Hodgkin’s lymphoma (NHL). The Zevalin therapeutic regimen is used to treat patients with: Low-grade or follicular B-cell NHL that has relapsed during or after treatment with other anticancer drugs; newly diagnosed follicular NHL following a response to initial anticancer therapy.